Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 17/20 | 1.00 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13991165 | 0.87 | CNR2 (1.00) | CNR2SIRT2SIRT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2736483 | 0.83 | CNR2 (0.71) | CNR2ALDH1A1 | |
| SCHEMBL216490 | 0.82 | CNR2 (0.69) | CNR2CNR1 | |
| SCHEMBL215835 | 0.77 | CNR2 (0.62) | CNR2SIRT2SIRT1ALDH1A1CNR1 | |
| SCHEMBL2736501 | 0.76 | CNR2 (0.74) | CNR2ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL2760217 | 0.76 | CNR2 (0.61) | CNR2SIRT2SIRT1ALDH1A1CNR1 | |
| SCHEMBL2736498 | 0.74 | CNR2 (0.73) | CNR2 | |
| SCHEMBL216609 | 0.72 | CNR2 (1.00) | CNR2ALDH1A1 | |
| SCHEMBL216181 | 0.72 | CNR2 (0.54) | CNR2CNR1 | |
| SCHEMBL2760076 | 0.70 | CNR2 (0.52) | CNR2ALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| EP-1477186-B1 | ANTIPRURITICS | SHIONOGI & CO (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-1357111-B1 | 2-PYRIDONE DERIVATIVES HAVING AFFINITY FOR CANNABINOID TYPE 2 RECEPTOR | SHIONOGI & CO (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20060052411-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | TADA YUKIO | 2006-03-09 | — | — | US | disclosed |
| US-6977266-B2 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | SHIONOGI & CO., LTD. (JP) | 2005-12-20 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040082619-A1 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | SHIONOGI & CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1357111-A1 | PYRIDONE DERIVATIVE HAVING AFFINITY FOR CANNABINOID 2-TYPE RECEPTOR | SHIONOGI & CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | CNR2 1/4885SIRT2 686/4885SIRT1 1202/4885 |
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | CNR2 2/4885SIRT2 3494/4885SIRT1 3545/4885 |
| US-20060052411-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | CNR2, CNR1, NPY2R | CNR2 1/4885SIRT2 932/4885SIRT1 1314/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | CNR2 2/4885SIRT2 3143/4885SIRT1 3074/4885 |
| US-20040082619-A1 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | CNR1, CNR2, NPY1R | CNR2 2/4885SIRT2 1513/4885SIRT1 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.